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Take home message: 
Among a nationwide cohort of renal transplant recipients (n=30,433), TB incidence was highest 
in the first year post-transplant. Asian ethnicity and CMV seropositivity were independent risk 
factors for post-transplant TB.  
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To the editor,  
 
Increased tuberculosis (TB) disease risk has consistently been observed among solid organ 
transplant recipients[1, 2]. This may result from post-transplant immunosuppressive therapy, 
although underlying disease processes leading to transplant (including chronic kidney disease) 
are also associated with increased risk[3]. TB among transplant recipients is associated with 
increased risk of drug toxicity, drug-drug interactions, graft failure, and mortality[4] and can 
lead to transmission to other vulnerable hospitalised patients. Consequently, global guidelines 
recommend systematic screening patients undergoing solid organ transplant for latent 
tuberculosis infection (LTBI)[3]. 
 
Renal transplants represent 70% of all transplants performed annually in the UK[5]. Few 
studies have examined the incidence of TB post-renal transplant in low TB incidence settings; 
these have reported incidence rates 17-30-fold higher than in the general population[1, 2, 4, 
6]. However, no studies have been conducted in the UK, and none have calculated ethnicity-
stratified rates. The latter is important as minority ethnic groups are over-represented among 
renal transplant recipients, and also at increased risk of TB disease.  
 
In England, Wales and Northern Ireland, the Enhanced TB Surveillance (ETS) system contains 
data on all TB notifications, while the UK Transplant Registry, held by NHS Blood and 
Transplant (NHSBT), provides national level data on transplant recipients. This includes 
detailed recipient characteristics, transplant information and annual post-transplant follow-up 
data on graft and patient survival. We aimed to utilise these datasets to investigate ethnicity-
stratified TB incidence rates among renal transplant recipients in the UK, and to examine risk 
factors for incident TB, to inform future testing and treatment policy.  
 
Data on renal transplant recipients in England, Wales and Northern Ireland from the UK 
Transplant Registry were deterministically matched with the ETS using unique NHS numbers 
3 
 
in order to idenfity transplant recipients who were notified with TB disease during the study 
period (January 2000 – December 2013).  
 
Renal transplant recipients entered the study cohort on the date of their first renal transplant 
during the study period. Follow-up was censored on the earliest date of: first TB diagnosis; 
death; or 31/12/2013 (the date of data extraction). Notified TB cases included culture-
confirmed TB or clinically diagnosed with radiological or histological evidence of TB, where a 
clinician had prescribed treatment with a full course of anti-TB treatment. The primary outcome 
measure was the crude post-transplant TB incidence rate, stratified by ethnicity (defined as 
either white, Asian (Indian, Pakistani or Bangladeshi), or ‘other’). Crude incidence rates were 
calculated per 100,000 person years, with 95% confidence intervals. Incidence rates were 
calculated during and after the first year post-transplant, since we hypothesised that TB risk 
would be highest in the initial months following transplantation, when the burden of 
immunosuppression is highest[2].  
 
Risk factors for incident TB among the transplant cohort were investigated using Cox 
regression with death as a competing risk, in view of the high mortality among the cohort. 
These included recipient age at transplant, gender, ethnicity, Cytomegalovirus (CMV) 
seropositivity, and co-infection with HIV, Hepatitis B and Hepatitic C. These variables are 
routinely collected by the UK Transplant Registry. Variables with p<0.2 in univariable analysis 
were included in the final multivariable model.  
 
Public Health England has authority under the Health and Social Care Act 2012 to hold and 
analyse national surveillance data for public health and research purposes. All patient data 
were fully anonymised prior to analysis. 
 
A total of 30,433 unique renal transplant recipients were included. Median age at entry to the 
cohort was 44 years (IQR 36-55), and a majority (18,723/30,433; 61.5%) of individuals were 
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male. A total of 24,951/30,433 (82.0%), 3,055/30,433 (10.0%) and 2,189/30,433 (7.2%) were 
of white, Asian and ‘other’ ethnicity, respectively. The majority of patients (28,305/30,433; 
93.0%) had single renal transplants only. CMV seropositivity was common, affecting 
12,658/30,433 (41.6%) of the cohort; this was more common among patients of Asian and 
‘other’ ethnicity, compared to the white ethnic group (9,291/24,951 (37.2%) in white group vs. 
1,899/3,055 (62.2%) in Asians and 1,371/2,189 (62.6%) in ‘other’ ethnic group). Conversely, 
only 147/30,433 (0.5%), 244/30,433 (0.8%) and 415/30,433 (1.4%) of patients were known to 
be co-infected with HIV, Hepatitis C virus and Hepatitis B virus, respectively. A total of 
3,299/30,433 (10.8%) transplants were done due to underlying diabetic renal disease. Median 
follow-up was 5.1 years (interquartile range (IQR) 2.2-8.7).  
 
Over 172,421 person-years of follow-up, 53/30,433 (0.17%) recipients were notified with 
incident TB, yielding an overall rate of 30.7/100,000 person-years (median time to incident TB 
among 53 cases was 1.4 years (IQR 0.6-4.0)). During follow-up, 3,486/30,433 (11.5%) 
individuals died (median time to death 3.6 years (IQR 0.9-6.7)).  
 
Among all ethnic groups, crude TB incidence rates were markedly higher in the first year post-
transplant than thereafter (30.0 vs. 11.6/100,000 person-years in white ethnic group; 289.8 
vs.125.5/100,000 person-years in Asian ethnic group; 199.0 vs.33.3/100,000 person-years in 
‘other’ ethnic group).  
 
In the multivariable competing risks regression analysis (Table 1), Asian ethnicity (compared 
to white) was a strong risk factor for developing incident TB (sub-distribution hazard ratio (sHR) 
11.0; 95% CI 5.28-22.91; p<0.001). Cytomegalovirus (CMV) seropositivity was also 





Of the 53 incident TB cases, 24 (45%) cases had pulmonary involvement, with the remainder 
notified as exclusively extra-pulmonary. Only one patient was notified with genitourinary TB. 
 
In this large population-based study examining incidence of TB post-renal transplantation, TB 
incidence varied markedly by recipient ethnicity, with highest incidence rates among Asian 
recipients. Among all ethnic groups, TB incidence was considerably higher in the first year 
post-transplant, suggesting that TB risk is associated with the initiation of post-transplant 
immunosuppression. The early onset of incident TB events post-transplant suggests that they 
are likely due to reactivation of latent infection, and therefore supports interventions such as 
provision of systematic screening for LTBI among patients of Asian and other non-white 
ethnicity being prepared for renal transplantation[3, 7]. This recommendation is reinforced by 
the previously observed severe sequelae of incident TB following renal transplant, including a 
higher risk of graft failure and mortality [4]. Among white transplant recipients, the overall post-
transplant TB incidence is markedly lower. An individual risk assessment which combines age 
and prior TB exposure could inform latent TB testing and treatment decisions in this group.  
 
CMV seropositivity was independently associated with incident TB among transplant 
recipients. This is consistent with data describing increased TB risk associated with CMV, 
which has led to the hypothesis that CMV co-infection may expedite progression from LTBI to 
TB disease via T cell activation[8, 9]. Further cohort studies and basic science research are 
needed to elucidate whether there is a causal association between CMV and TB, and to rule 
out residual confounding by ethnicity, socioeconomic status or immune susceptibility as 
alternative explanations. 
 
Strengths of this study include the comprehensive, nationwide study cohort over a 14-year 
period. Data completeness for key variables was also very high (99.2% for ethnicity; 82-89.1% 
for viral co-infection screening). A weakness is that no data were available on previous TB 
disease or LTBI screening pre-transplant, or the provision of TB preventative therapy (which 
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is heterogeneous among transplant centres in the UK[7, 10]). If a large proportion of transplant 
recipients received prior TB or LTBI therapy, this may have reduced our observed TB incidence 
rates. Second, our data linkage procedure may have failed to identify some incident TB cases, 
since NHS numbers were available for approximately 70% of ETS notifications during the study 
period, while some transplant patients may also have emigrated during follow-up. The 
calculated post-transplant incidence rates should therefore be considered as minimum 
estimates. However, the effect of incomplete linkage is likely non-differential and therefore 
limited our ability to detect associations rather than creating false associations. Further, NHS 
number is more likely to be available in ETS for transplant recipients (who are well engaged in 
NHS care), which would therefore reduce our risk of missing post-transplant TB cases. Finally, 
available data on country of birth were incomplete, and therefore not included in the analysis. 
 
In summary, we have demonstrated that post-transplant TB incidence is markedly higher 
among Asian and ‘other’ ethnic groups than the white ethnic group. Ethnicity-stratified TB 
incidence rates are elevated during the first year post-renal transplant among all ethnic groups. 
These data support UK guidance recommending systematic LTBI screening among patients 
being prepared for transplant who are thought to be at high risk of TB. In addition to Asian 
ethnicity, CMV seropositivity was an independent risk factor for incident TB. The mechanism 
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Table 1: Results of univariable and multivariable (n=24,014) competing risks Cox regression analysis of risk factors for incident tuberculosis 
among renal transplant cohort. sHR = subdistribution hazard ratio; CI = confidence interval; ref = reference category. Data displayed with 95% 




TB cases Person-years Incidence rate Univariable Multivariable    
(100,000s) (per 100,000) sHR p sHR p 
         




(years) ≥30 49 1.38 35.4 (26.8-46.9) 2.68 (0.97-7.41) 0.060 1.54 (0.52-4.51) 0.433          
Gender Male 33 1.05 31.3 (22.3-44.1) ref 
   
 
Female 20 0.67 29.8 (19.2-46.2) 0.96 (0.55-1.68) 0.898 
  
         





Asian 24 0.16 154.8 (103.7-230.9) 10.14 (5.66-18.17) <0.001 11.0 (5.28-22.91) <0.001  
Other 7 0.11 63.6 (30.3-133.4) 4.15 (1.77-9.74) 0.001 2.77 (0.85-9) 0.090          
Cytomegalovirus IgG Positive 33 0.67 49.5 (35.2-69.6) 4.27 (2.05-8.91) <0.001 2.42 (1.03-5.68) 0.043  




         
Hepatitis B Positive 2 0.02 116.0 (29.0-464.0) 3.1 (0.75-12.83) 0.119 1.52 (0.39-5.87) 0.541  




         
Hepatitis C Positive 2 0.01 163.9 (41-655.3) 4.8 (1.16-19.92) 0.031 3.61 (0.91-14.41) 0.069  
Negative 42 1.25 33.7 (24.9-45.5) ref 
 
ref 
 
 
 
 
